Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases

References

• Chambers ES, Vukmanovic-Stejic M. Skin barrier immunity and ageing. Immunology. 2020;160(2):116–14. doi:10.1111/imm.13152.
   PubMed Web of Science ®Google Scholar
• Matejuk A. Skin immunity. Arch Immunol Ther Exp (Warsz). 2018;66(1):45–54. doi:10.1007/s00005-017-0477-3.
   PubMed Web of Science ®Google Scholar
• Brandner JM, Zorn-Kruppa M, Yoshida T, Moll I, Beck LA, De Benedetto A. Epidermal tight junctions in health and disease. Tissue Barriers. 2015;3(1–2):e974451. doi:10.4161/21688370.2014.974451.
   PubMed Web of Science ®Google Scholar
• Tan Y, Tey HL, Chong SZ, Ng LG. Skinny deeping: uncovering immune cell behavior and function through imaging techniques. Immunol Rev. 2022;306(1):271–92. doi:10.1111/imr.13049.
   PubMed Web of Science ®Google Scholar
• Darlenski R, Kazandjieva J, Hristakieva E, Fluhr JW. Atopic dermatitis as a systemic disease. Clin Dermatol. 2014;32(3):409–13. doi:10.1016/j.clindermatol.2013.11.007.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Kodama S. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36(5):648–52. doi:10.1016/j.clindermatol.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Traineau H, Aggarwal R, Monfort JB, Senet P, Oddis CV, Chizzolini C, Barbaud A, Francès C, Arnaud L, Chasset F. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. J Am Acad Dermatol. 2020;82(2):317–25. doi:10.1016/j.jaad.2019.07.006.
   PubMed Web of Science ®Google Scholar
• Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641–50. doi:10.1002/jor.1100090504.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Dj P, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–17. doi:10.1080/14653240600855905.
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2(1):8. doi:10.1186/1476-9255-2-8.
   PubMedGoogle Scholar
• Koppula PR, Chelluri LK, Polisetti N, Vemuganti GK. Histocompatibility testing of cultivated human bone marrow stromal cells - a promising step towards pre-clinical screening for allogeneic stem cell therapy. Cell Immunol. 2009;259(1):61–65. doi:10.1016/j.cellimm.2009.05.014.
   PubMed Web of Science ®Google Scholar
• Li C, Zhao H, Cheng L, Wang B. Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell Biosci. 2021;11(1):187. doi:10.1186/s13578-021-00698-y.
   PubMed Web of Science ®Google Scholar
• Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev. 2006;2(2):155–62. doi:10.1007/s12015-006-0022-y.
   PubMed Web of Science ®Google Scholar
• Matsiko A, Levingstone TJ, O’Brien FJ. Advanced strategies for articular cartilage defect repair. Materials (Basel). 2013;6(2):637–68. doi:10.3390/ma6020637.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu Y, Chen Y, Yuan L, Liu H, Wang J, Liu Q, Zhang Y. Adipose-derived stem cells: current applications and future directions in the regeneration of multiple tissues. Stem Cells Int. 2020;2020:8810813. doi:10.1155/2020/8810813.
   PubMed Web of Science ®Google Scholar
• Musiał-Wysocka A, Kot M, Majka M. The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant. 2019;28(7):801–12. doi:10.1177/0963689719837897.
   PubMed Web of Science ®Google Scholar
• Li Y, Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 2012;120(17):3436–43. doi:10.1182/blood-2012-03-420612.
   PubMed Web of Science ®Google Scholar
• Li Y, Fung J, Lin F. Local inhibition of complement improves mesenchymal stem cell viability and function after administration. Mol Ther. 2016;24(9):1665–74. doi:10.1038/mt.2016.142.
   PubMed Web of Science ®Google Scholar
• Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 2010;19(11):1803–09. doi:10.1089/scd.2009.0418.
   PubMed Web of Science ®Google Scholar
• Li Y, Qiu W, Zhang L, Fung J, Lin F. Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage. Biomaterials. 2016;102:209–19. doi:10.1016/j.biomaterials.2016.05.055.
   PubMed Web of Science ®Google Scholar
• Taghavi-Farahabadi M, Mahmoudi M, Hashemi SM, Rezaei N. Evaluation of the effects of mesenchymal stem cells on neutrophils isolated from severe congenital neutropenia patients. Int Immunopharmacol. 2020;83:106463. doi:10.1016/j.intimp.2020.106463.
   PubMed Web of Science ®Google Scholar
• Wang G, Joel M, Yuan J, Wang J, Cai X, Ocansey D, Yan Y, Qian H, Zhang X, Xu W, et al. Human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease by inhibiting ERK phosphorylation in neutrophils. Inflammopharmacology. 2020;28(2):603–16. doi:10.1007/s10787-019-00683-5.
   PubMed Web of Science ®Google Scholar
• Jiang D, Muschhammer J, Qi Y, Kügler A, de Vries JC, Saffarzadeh M, Sindrilaru A, Beken SV, Wlaschek M, Kluth MA, et al. Suppression of neutrophil-mediated tissue damage—a novel skill of mesenchymal stem cells. Stem Cells. 2016;34(9):2393–406. doi:10.1002/stem.2417.
   PubMed Web of Science ®Google Scholar
• Requena J, Alvarez-Palomo AB, Codina-Pascual M, Delgado-Morales R, Moran S, Esteller M, Sal M, Juan M, Boronat Barado A, Consiglio A, et al. Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling. Stem Cells. 2019;37(4):476–88. doi:10.1002/stem.2966.
   PubMed Web of Science ®Google Scholar
• Hackel A, Aksamit A, Bruderek K, Lang S, Brandau S. TNF-α and IL-1β sensitize human MSC for IFN-γ signaling and enhance neutrophil recruitment. Eur J Immunol. 2021;51(2):319–30. doi:10.1002/eji.201948336.
   PubMed Web of Science ®Google Scholar
• Vasandan AB, Jahnavi S, Shashank C, Prasad P, Kumar A, Prasanna SJ. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE(2)-dependent mechanism. Sci Rep. 2016;6(1):38308. doi:10.1038/srep38308.
   PubMedGoogle Scholar
• Jin L, Deng Z, Zhang J, Yang C, Liu J, Han W, Ye P, Si Y, Chen G. Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy. J Transl Med. 2019;17(1):251. doi:10.1186/s12967-019-1999-8.
   PubMed Web of Science ®Google Scholar
• Stone Ii R, Natesan S, Kowalczewski CJ, Mangum LH, Clay NE, Clohessy RM, Carlsson AH, Tassin DH, Chan RK, Rizzo JA, et al. Advancements in regenerative strategies through the continuum of burn care. Front Pharmacol. 2018;9:672. doi:10.3389/fphar.2018.00672.
   PubMed Web of Science ®Google Scholar
• Sierra-Sánchez Á, Montero-Vilchez T, Quiñones-Vico MI, Sanchez-Diaz M, Arias-Santiago S. Current advanced therapies based on human mesenchymal stem cells for skin diseases. Front Cell Dev Biol. 2021;9:643125. doi:10.3389/fcell.2021.643125.
   PubMed Web of Science ®Google Scholar
• Wu P, Zhang B, Shi H, Qian H, Xu W. MSC-exosome: a novel cell-free therapy for cutaneous regeneration. Cytotherapy. 2018;20(3):291–301. doi:10.1016/j.jcyt.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–58. doi:10.1002/stem.2575.
   PubMed Web of Science ®Google Scholar
• Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol. 2021;12:749192. doi:10.3389/fimmu.2021.749192.
   PubMed Web of Science ®Google Scholar
• Cho KA, Cha JE, Kim J, Kim YH, Ryu KH, Woo SY. Mesenchymal stem cell-derived exosomes attenuate TLR7-mediated mast cell activation. Tissue Eng Regen Med. 2022;19(1):117–29. doi:10.1007/s13770-021-00395-4.
   PubMed Web of Science ®Google Scholar
• Liu J, Kuwabara A, Kamio Y, Hu S, Park J, Hashimoto T, Lee JW. Human mesenchymal stem cell-derived microvesicles prevent the rupture of intracranial aneurysm in part by suppression of mast cell activation via a PGE2-dependent mechanism. Stem Cells. 2016;34(12):2943–55. doi:10.1002/stem.2448.
   PubMed Web of Science ®Google Scholar
• Bogatcheva NV, Coleman ME. Conditioned medium of mesenchymal stromal cells: a new class of therapeutics. Biochemistry (Mosc). 2019;84(11):1375–89. doi:10.1134/S0006297919110129.
   PubMed Web of Science ®Google Scholar
• Montero-Vilchez T, Sierra-Sánchez Á, Sanchez-Diaz M, Quiñones-Vico MI, Sanabria-de-la-Torre R, Martinez-Lopez A, Arias-Santiago S. Mesenchymal stromal cell-conditioned medium for skin diseases: a systematic review. Front Cell Dev Biol. 2021;9:654210. doi:10.3389/fcell.2021.654210.
   PubMedGoogle Scholar
• Griffiths C, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–15. doi:10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis D, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–113. doi:10.1016/j.jaad.2018.11.058.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin K, Mørk C, Jahnsen J, Kvien TK. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16. doi:10.1016/S0140-6736(17)30068-5.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–39. doi:10.1016/S0140-6736(18)32167-6.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496–505. doi:10.1016/S0140-6736(20)30564-X.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–39. doi:10.1016/S0140-6736(19)31773-8.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60. doi:10.1001/jama.2020.4006.
   PubMed Web of Science ®Google Scholar
• Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E. Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol. 2018;19(2):209–22. doi:10.1007/s40257-017-0322-9.
   PubMed Web of Science ®Google Scholar
• Sah SK, Park KH, Yun CO, Kang KS, Kim TY. Effects of human mesenchymal stem cells transduced with superoxide dismutase on imiquimod-induced psoriasis-like skin inflammation in mice. Antioxid Redox Signal. 2016;24(5):233–48. doi:10.1089/ars.2015.6368.
   PubMed Web of Science ®Google Scholar
• Lee YS, Sah SK, Lee JH, Seo KW, Kang KS, Kim TY. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice. Biochem Biophys Rep. 2017;9:281–88. doi:10.1016/j.bbrep.2016.10.002.
   PubMedGoogle Scholar
• Chen M, Peng J, Xie Q, Xiao N, Su X, Mei H, Lu Y, Zhou J, Dai Y, Wang S, et al. Mesenchymal stem cells alleviate moderate-to-severe psoriasis by reducing the production of type I interferon (IFN-I) by plasmacytoid dendritic cells (pDCs). Stem Cells Int. 2019;2019:6961052. doi:10.1155/2019/6961052.
   PubMed Web of Science ®Google Scholar
• Zhang B, Lai RC, Sim WK, Choo A, Lane EB, Lim SK. Topical application of mesenchymal stem cell exosomes alleviates the imiquimod induced psoriasis-like inflammation. Int J Mol Sci. 2021;22(2):720. doi:10.3390/ijms22020720.
   PubMed Web of Science ®Google Scholar
• Ahn H, Lee SY, Jung WJ, Pi J, Lee KH. Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: a case report. World J Clin Cases. 2021;9(23):6798–803. doi:10.12998/wjcc.v9.i23.6798.
   PubMed Web of Science ®Google Scholar
• Chen H, Niu JW, Ning HM, Pan X, Li XB, Li Y, Wang DH, Hu LD, Sheng HX, Xu M, et al. Treatment of psoriasis with mesenchymal stem cells. Am J Med. 2016;129(3):e13–14. doi:10.1016/j.amjmed.2015.11.001.
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99. doi:10.1016/S0140-6736(17)30933-9.
   PubMed Web of Science ®Google Scholar
• Sierra-Sepúlveda A, Esquinca-González A, Benavides-Suárez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castañeda AR, Rodríguez-Reyna TS. Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. Biomed Res Int. 2019;2019:4569826. doi:10.1155/2019/4569826.
   PubMed Web of Science ®Google Scholar
• Farina A, Cirone M, York M, Lenna S, Padilla C, Mclaughlin S, Faggioni A, Lafyatis R, Trojanowska M, Farina GA. Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol. 2014;134(4):954–64. doi:10.1038/jid.2013.423.
   PubMed Web of Science ®Google Scholar
• Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018;195:76–82. doi:10.1016/j.imlet.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39. doi:10.1136/annrheumdis-2016-209909.
   PubMed Web of Science ®Google Scholar
• Agostini E, De Luca G, Bruni C, Bartoli F, Tofani L, Campochiaro C, Pacini G, Moggi-Pignone A, Guiducci S, Bellando-Randone S, et al. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from systematic literature review and from real life experience. Autoimmun Rev. 2021;20(12):102981. doi:10.1016/j.autrev.2021.102981.
   PubMed Web of Science ®Google Scholar
• Khaki M, Salmanian AH, Abtahi H, Ganji A, Mosayebi G. Mesenchymal stem cells differentiate to endothelial cells using recombinant vascular endothelial growth factor -A. Rep Biochem Mol Biol. 2018;6:144–50.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen L, Zhang G, Zhang B. Umbilical cord-matrix stem cells induce the functional restoration of vascular endothelial cells and enhance skin wound healing in diabetic mice via the polarized macrophages. Stem Cell Res Ther. 2020;11(1):39. doi:10.1186/s13287-020-1561-x.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li S, Wang Y, Zhang X, Chen L, Sun D. GDNF enhances the anti-inflammatory effect of human adipose-derived mesenchymal stem cell-based therapy in renal interstitial fibrosis. Stem Cell Res. 2019;41:101605. doi:10.1016/j.scr.2019.101605.
   PubMed Web of Science ®Google Scholar
• Chen X, Wu Y, Wang Y, Chen L, Zheng W, Zhou S, Xu H, Li Y, Yuan L, Xiang C. Human menstrual blood-derived stem cells mitigate bleomycin-induced pulmonary fibrosis through anti-apoptosis and anti-inflammatory effects. Stem Cell Res Ther. 2020;11(1):477. doi:10.1186/s13287-020-01926-x.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun D. Adipose-derived mesenchymal stem cells: a new tool for the treatment of renal fibrosis. Stem Cells Dev. 2018;27(20):1406–11. doi:10.1089/scd.2017.0304.
   PubMed Web of Science ®Google Scholar
• Minteer DM, Marra KG, Rubin JP. Adipose stem cells: biology, safety, regulation, and regenerative potential. Clin Plast Surg. 2015;42(2):169–79. doi:10.1016/j.cps.2014.12.007.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, Minniti A, Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther. 2019;21(1):7. doi:10.1186/s13075-018-1792-8.
   PubMedGoogle Scholar
• Maria AT, Toupet K, Maumus M, Fonteneau G, Le Quellec A, Jorgensen C, Guilpain P, Noël D. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. J Autoimmun. 2016;70:31–39. doi:10.1016/j.jaut.2016.03.013.
   PubMed Web of Science ®Google Scholar
• Rubio GA, Elliot SJ, Wikramanayake TC, Xia X, Pereira-Simon S, Thaller SR, Glinos GD, Jozic I, Hirt P, Pastar I, et al. Mesenchymal stromal cells prevent bleomycin-induced lung and skin fibrosis in aged mice and restore wound healing. J Cell Physiol. 2018;233(8):5503–12. doi:10.1002/jcp.26418.
   PubMed Web of Science ®Google Scholar
• Gheisari M, Ahmadzadeh A, Nobari N, Iranmanesh B, Mozafari N. Autologous fat grafting in the treatment of facial scleroderma. Dermatol Res Pract. 2018;2018:6568016. doi:10.1155/2018/6568016.
   PubMed Web of Science ®Google Scholar
• Granel B, Daumas A, Jouve E, Harlé JR, Nguyen PS, Chabannon C, Colavolpe N, Reynier JC, Truillet R, Mallet S, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2015;74(12):2175–82. doi:10.1136/annrheumdis-2014-205681.
   PubMed Web of Science ®Google Scholar
• Marangoni RG, Korman BD, Wei J, Wood TA, Graham LV, Whitfield ML, Scherer PE, Tourtellotte WG, Varga J. Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol. 2015;67(4):1062–73. doi:10.1002/art.38990.
   PubMed Web of Science ®Google Scholar
• Taki Z, Gostjeva E, Thilly W, Yaseen B, Lopez H, Mirza M, Hassuji Z, Vigneswaran S, Ahmed Abdi B, Hart A, et al. Pathogenic activation of mesenchymal stem cells is induced by the disease microenvironment in systemic sclerosis. Arthritis Rheumatol. 2020;72(8):1361–74. doi:10.1002/art.41267.
   PubMed Web of Science ®Google Scholar
• Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, Mazzanti B, Dal Pozzo S, Milia AF, Bellando-Randone S, et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med. 2010;153(10):650–54. doi:10.7326/0003-4819-153-10-201011160-00007.
   PubMed Web of Science ®Google Scholar
• Fonteneau G, Bony C, Goulabchand R, Maria A, Le Quellec A, Rivière S, Jorgensen C, Guilpain P, Noël D. Serum-mediated oxidative stress from systemic sclerosis patients affects mesenchymal stem cell function. Front Immunol. 2017;8:988. doi:10.3389/fimmu.2017.00988.
   PubMed Web of Science ®Google Scholar
• DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–81. doi:10.1016/j.jaad.2019.06.1309.
   PubMed Web of Science ®Google Scholar
• Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol. 2017;8:992. doi:10.3389/fimmu.2017.00992.
   PubMed Web of Science ®Google Scholar
• Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239–47. doi:10.1002/art.38137.
   PubMed Web of Science ®Google Scholar
• Miyashiro D, Arnone M, Ferreira PS, Romiti R, Sanches JA. Extensive cutaneous involvement by dermatomyositis: report of six cases and review of the literature. Autoimmun Rev. 2020;19(12):102680. doi:10.1016/j.autrev.2020.102680.
   PubMed Web of Science ®Google Scholar
• Callen JP. Dermatomyositis. Lancet. 2000;355(9197):53–57. doi:10.1016/S0140-6736(99)05157-0.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, Wang H, Hua B, Liu B, Sun L. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70(7):1285–88. doi:10.1136/ard.2010.141804.
   PubMed Web of Science ®Google Scholar
• Zhu J, Su G, Lai J, Dong B, Kang M, Li S, Zhou Z, Wu F. Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. Pediatr Rheumatol Online J. 2018;16(1):72. doi:10.1186/s12969-018-0284-3.
   PubMedGoogle Scholar
• Bawany F, Tbakhi B, Mendler JH, Richardson CT, Bennett JM, Aljitawi OS. Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome. Blood Adv. 2020;4(22):5698–701. doi:10.1182/bloodadvances.2020003104.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60. doi:10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–39. doi:10.1056/NEJMoa1314768.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. doi:10.1016/S0140-6736(17)31191-1.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49. doi:10.1111/bjd.19574.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–84. doi:10.1016/j.jaci.2019.11.025.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Schreiber S. Abrocitinib for atopic dermatitis: a step forward. Lancet. 2020;396(10246):215–17. doi:10.1016/S0140-6736(20)31284-8.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–55. doi:10.1111/bjd.18898.
   PubMed Web of Science ®Google Scholar
• Kim HS, Yun JW, Shin TH, Lee SH, Lee BC, Yu KR, Seo Y, Lee S, Kang TW, Choi SW, et al. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-β1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells. 2015;33(4):1254–66. doi:10.1002/stem.1913.
   PubMed Web of Science ®Google Scholar
• Orciani M, Campanati A, Caffarini M, Ganzetti G, Consales V, Lucarini G, Offidani A, Di Primio R. T helper (Th)1, Th17 and Th2 imbalance in mesenchymal stem cells of adult patients with atopic dermatitis: at the origin of the problem. Br J Dermatol. 2017;176(6):1569–76. doi:10.1111/bjd.15078.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee SH, Kim Y, Kwon Y, Park Y, Lee HK, Jung HS, Jeoung D. Human adipose tissue-derived mesenchymal stem cells attenuate atopic dermatitis by regulating the expression of MIP-2, miR-122a-SOCS1 Axis, and Th1/Th2 Responses. Front Pharmacol. 2018;9:1175. doi:10.3389/fphar.2018.01175.
   PubMed Web of Science ®Google Scholar
• Ryu B, Baek J, Kim H, Lee JH, Kim J, Jeong YH, Lee SG, Kang KR, Oh MS, Kim EY, et al. Anti-inflammatory effects of M-MSCs in DNCB-induced atopic dermatitis mice. Biomedicines. 2020;8(10):439. doi:10.3390/biomedicines8100439.
   PubMed Web of Science ®Google Scholar
• Na K, Yoo HS, Zhang YX, Choi MS, Lee K, Yi TG, Song SU, Jeon MS. Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis. Cell Death Dis. 2014;5(7):e1345. doi:10.1038/cddis.2014.299.
   PubMedGoogle Scholar
• Shin KO, Ha DH, Kim JO, Crumrine DA, Meyer JM, Wakefield JS, Lee Y, Kim B, Kim S, Kim HK, et al. Exosomes from human adipose tissue-derived mesenchymal stem cells promote epidermal barrier repair by inducing de novo synthesis of ceramides in atopic dermatitis. Cells. 2020;9(3):680. doi:10.3390/cells9030680.
   PubMed Web of Science ®Google Scholar
• Song JY, Kang HJ, Ju HM, Park A, Park H, Hong JS, Kim CJ, Shim JY, Yu J, Choi J. Umbilical cord-derived mesenchymal stem cell extracts ameliorate atopic dermatitis in mice by reducing the T cell responses. Sci Rep. 2019;9(1):6623. doi:10.1038/s41598-019-42964-7.
   PubMed Web of Science ®Google Scholar
• Lee BC, Kim JJ, Lee JY, Kang I, Shin N, Lee SE, Choi SW, Cho JY, Kim HS, Kang KS. Disease-specific primed human adult stem cells effectively ameliorate experimental atopic dermatitis in mice. Theranostics. 2019;9(12):3608–21. doi:10.7150/thno.32945.
   PubMed Web of Science ®Google Scholar
• Pierce LM, Kurata WE. Priming with toll-like receptor 3 agonist poly(I:C) enhances content of innate immune defense proteins but not MicroRNAs in human mesenchymal stem cell-derived extracellular vesicles. Front Cell Dev Biol. 2021;9:676356. doi:10.3389/fcell.2021.676356.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JH, Roh KH, Jun HJ, Kang KS, Kim TY. Clinical trial of human umbilical cord blood-derived stem cells for the treatment of moderate-to-severe atopic dermatitis: phase I/IIa studies. Stem Cells. 2017;35(1):248–55. doi:10.1002/stem.2401.
   PubMed Web of Science ®Google Scholar
• Shin HT, Lee SH, Yoon HS, Heo JH, Lee SB, Byun JW, Shin J, Cho YK, Chung E, Jeon MS, et al. Long-term efficacy and safety of intravenous injection of clonal mesenchymal stem cells derived from bone marrow in five adults with moderate to severe atopic dermatitis. J Dermatol. 2021;48(8):1236–42. doi:10.1111/1346-8138.15928.
   PubMed Web of Science ®Google Scholar